Drugs / LP2307
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00726739 | Jun 2008 → Jun 2011 | melanoma | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LP2307 | “To compare the progression-free survival of patients with stage IV melanoma treated with aldesleukin with vs without allogeneic large multivalent immunogen melanoma vaccine LP2307.” NCT00726739 ↗ |
| Modality | Vaccine | “melanoma vaccine LP2307” NCT00726739 ↗ |
| Route | Other | “will be given as an intradermal injection” NCT00726739 ↗ |